CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.
All CIRM Grants
Search Filters »
| Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
| City of Hope, Beckman Research Institute |
Prof. Karen S Aboody M.D. |
Disease Team Research I |
Stem Cell-mediated Therapy for High-grade Glioma: Toward Phase I-II Clinical Trials |
$17,890,623 |
| Stanford University |
Dr. Alfred T Lane |
Disease Team Research I |
iPS Cell-Based Treatment of Dominant Dystrophic Epidermolysis Bullosa |
$11,039,208 |
| Stanford University |
Professor Irving L Weissman MD |
Disease Team Research I |
Development of Therapeutic Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells |
$18,759,276 |
| University of California, Los Angeles |
Dr. Dennis J Slamon |
Disease Team Research I |
Therapeutic Opportunities To Target Tumor Initiating Cells in Solid Tumors |
$19,979,660 |
| City of Hope, Beckman Research Institute |
Prof. John A. Zaia |
Disease Team Research I |
ZINC FINGER NUCLEASE-BASED STEM CELL THERAPY FOR AIDS |
$14,536,969 |
| University of Southern California |
Mark Salman Humayun |
Disease Team Research I |
Stem cell based treatment strategy for Age-related Macular Degeneration (AMD) |
$18,904,916 |
| University of California, San Diego |
Dr. Dennis A Carson |
Disease Team Research I |
Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT) |
$19,999,826 |
| University of California, San Diego |
Dr. Gene Wei-Ming Yeo |
Basic Biology I |
RNA Binding Protein-mediated Post-transcriptional Networks Regulating HPSC Pluripotency |
$1,308,901 |
| University of California, San Diego |
Karl H. Willert |
Basic Biology I |
WNT signaling and the control of cell fate decisions in human pluripotent stem cells. |
$1,329,298 |
| University of California, Davis |
Dr. Min Zhao |
Basic Biology I |
Directing migration of human stem cells with electric fields |
$816,228 |
| University of California, Los Angeles |
Dr. Michael A. Teitell |
Basic Biology I |
Mitochondrial Metabolism in hESC and hiPSC Differentiation, Reprogramming, and Cancer |
$1,323,029 |
| University of Southern California |
Dr. Martin Pera |
Basic Biology I |
The stem cell microenvironment in the maintenance of pluripotency and reprogramming |
$1,325,723 |
| Stanford University |
Dr. Julien Sage |
Basic Biology I |
The retinoblastoma (RB) gene family in cellular reprogramming |
$1,357,085 |
| Stanford University |
Dr. Susan K McConnell |
Basic Biology I |
Identification and characterization of human ES-derived DA neuronal subtypes |
$1,404,853 |
| University of California, Los Angeles |
Bennett G Novitch |
Basic Biology I |
Molecular Characterization of hESC and hIPSC-Derived Spinal Motor Neurons |
$1,228,278 |
| University of California, Los Angeles |
Dr. Robb Maclellan Dr. |
Basic Biology I |
Human Cardiovascular Progenitors, their Niches and Control of Self-renewal and Cell Fate |
$917,667 |
| University of Southern California |
Dr. Wange Lu |
Basic Biology I |
Defining the molecular mechanisms of somatic cell reprogramming |
$1,365,580 |
| Stanford University |
Professor Helen M. Blau PhD |
Basic Biology I |
Molecular Mechanisms of Reprogramming towards Pluripotency |
$1,408,332 |
| University of California, Los Angeles |
Dr. Luisa Iruela-Arispe |
Basic Biology I |
Molecular Characterization and Functional Exploration of Hemogenic Endothelium |
$1,371,477 |
| University of California, Davis |
Dr. Frederick J Meyers MD |
Training Grant I-1 |
Stem Cell Research Training Grant |
$1,780,859 |
| University of California, San Francisco |
Dr. Susan J Fisher PhD |
Training Grant I-1 |
Training Grant I |
$2,868,145 |
| University of California, Los Angeles |
Dr. Owen N Witte M.D. |
Training Grant I-1 |
CIRM Type I Comprehensive Training Program |
$3,660,398 |
| University of Southern California |
Dr. Robert E Maxson |
Training Grant I-1 |
CIRM Stem Cell Biology Training Grant |
$2,332,431 |
| University of California, Irvine |
Dr. Peter Bryant |
Training Grant I-1 |
Stem Cell Research Training Grant |
$1,935,487 |
| University of California, Berkeley |
Randy W. Schekman |
Training Grant I-1 |
Human Stem Cell Training at UC Berkeley and Childrens Hospital of Oakland |
$2,360,457 |
| University of California, San Diego |
Dr. Lawrence S. B. Goldstein |
Training Grant I-1 |
Interdisciplinary Stem Cell Training Program at UCSD |
$3,459,396 |
| Stanford University |
Dr. Michael T Longaker MD, PhD |
Training Grant I-1 |
Stanford CIRM Training Program |
$3,035,282 |
| University of California, Davis |
Dr Mehrdad Abedi |
Disease Team Therapy Planning I |
Stem Cell Gene Therapy for HIV in AIDS Lymphoma Patients |
$66,880 |
| University of California, Davis |
Dr. John Laird |
Disease Team Therapy Planning I |
Phase I study of IM Injection of VEGF Producing MSC for the Treatment of Critical Limb Ischemia |
$76,066 |
| University of California, Davis |
Dr. Vicki Wheelock |
Disease Team Therapy Planning I |
MSC engineered to produce BDNF for the treatment of Huntington’s disease |
$97,564 |
| Cedars-Sinai Medical Center |
Professor Clive Niels Svendsen |
Disease Team Therapy Planning I |
Stem Cells Secreting GDNF for the Treatment of ALS |
$63,487 |
| Stanford University |
Dr. Albert J Wong |
Disease Team Therapy Planning I |
Recombinant Bispecific Antibody Targeting Cancer Stem Cells for the Therapy of Glioblastoma |
$109,750 |
| Stanford University |
Dr. Judith A Shizuru |
Disease Team Therapy Planning I |
A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants |
$90,147 |
| OncoMed Pharmaceuticals, Inc. |
Timothy Hoey |
Disease Team Therapy Planning I |
Anti-Notch1, OMP-52M51: A New Cancer Therapeutic to Reduce CSC Frequency |
$65,120 |
| Cedars-Sinai Medical Center |
Dr. Dan Gazit |
Disease Team Therapy Planning I |
Genetically Engineered Mesenchymal Stem Cells for the Treatment of Vertebral Compression Fractures. |
$107,622 |
| StemCells, Inc. |
Dr. Alexandra Capela |
Disease Team Therapy Planning I |
Neuroprotection to treat Alzheimer’s: a new paradigm using human central nervous system cells |
$90,101 |
| University of California, Los Angeles |
Dr. Stanley Nelson |
Disease Team Therapy Planning I |
Combination therapy to Enhance Antisense Mediated Exon Skipping for Duchenne Muscular Dystrophy |
$68,947 |
| Geron Corporation |
Dr. Jane Stephanie Lebkowski Dr. |
Disease Team Therapy Planning I |
Preclinical Development and First-In-Human Testing of GRNCM1 in Advanced Heart Failure |
$0 |
| Sanford Burnham Prebys Medical Discovery Institute |
Dr. Marcel Daadi Dr. |
Disease Team Therapy Planning I |
Neural Stem Cell-Based Therapy For Parkinson’s Disease |
$63,952 |
| Sanford Burnham Prebys Medical Discovery Institute |
Dr. Stuart A Lipton |
Disease Team Therapy Planning I |
hESC-derived NPCs Programmed with MEF2C for Cell Transplantation in Parkinson’s Disease |
$96,448 |
| University of California, Davis |
Nancy E. Lane |
Disease Team Therapy Planning I |
Increasing the endogenous mesenchymal stem cells to the bone surface to treat osteoporosis |
$107,750 |
| University of Southern California |
Roberta Diaz Brinton |
Disease Team Therapy Planning I |
A CIRM Disease Team to Develop Allopregnanolone for Prevention and Treatment of Alzheimer’s Disease |
$107,961 |
| Samumed, LLC |
John Hood |
Disease Team Therapy Planning I |
Clinical Development of an osteoinductive therapy to prevent osteoporosis-related fractures |
$99,110 |
| Stanford University |
Dr. Robert Robbins |
Disease Team Therapy Planning I |
Human Embryonic Stem Cell-Derived Cardiomyocytes for Patients with End Stage Heart Failure |
$73,030 |
| University of California, Davis |
Dr. Martin Birchall |
Disease Team Therapy Planning I |
Airways for Children |
$19,800 |
| University of California, Los Angeles |
Dr. Antoni Ribas MD/PhD |
Disease Team Therapy Planning I |
Genetic Re-programming of Stem Cells to Fight Cancer |
$97,785 |
| California State University San Marcos Corporation |
Dr. Bianca Romina Mothé |
Bridges |
California State University-San Marcos CIRM Bridges to the Stem Cell Research Training Grant |
$4,114,712 |
| Cal State Univ, Long Beach |
Dr. Lisa S Klig |
Bridges |
CIRM Stem Cell Research Biotechnology Training Program at CSULB |
$3,487,091 |
| Cal Poly Pomona Foundation |
Dr. Jill Adler-Moore |
Bridges |
Cal Poly Pomona and Cal State LA Collaborative CIRM Bridges Program to Enhance Stem Cell Research Training and Education |
$3,056,191 |
| San Francisco State University |
Dr. Carmen Domingo |
Bridges |
SFSU Bridges to Stem Cell Research |
$4,168,243 |